Factory supply Voglibose Cas 83480-29-9 with high quality and best price CAS NO.83480-29-9

Professional supplier Voglibose Cas 83480-29-9 with superior quality

Company profile

Wuhan Fortuna Chemical Co.,Ltd established in 2006, is a big integrative chemical enterprise being engaged in Pharmaceutical & its intermediates, Food/Feed additives, Fine chemicals in distributing the products of our own company and affiliated enterprises, are the members of Hubei E-commerce Chamber.

Our company has professional persons who major in chemical R&D and sicentific management, supply fine chemical products with high quality and close service, also supply custom-tailored products according to our clients’ requirement.

We have a positive and self-motivated management work team with a common philosophy, caring and commitment through teamwork, our team strive to achieve success in delighting our clients and ourselves. 

Since Wuhan Fortuna Chemical Co., Ltd founded, we continuously innovate our products and improve our service, sales network. Hence, we initiate the first sale mode on net in China, which is the retail trade of small package bring along wholesale of diversified management modes. Our products are exported widely to South Korea, Vietnam, Australia, Europe and South America, highly recommended by our clients.

We insist on the management creed “Market is our compass, Quality is our life, Credit is our soul”. Clients’ trust is our forward powder, their satisfaction is our struggling goal.

our competitive advantage

Guaranteed purity

High quality & competitive price

Quality control

Fast feedback

Prompt shipment

Voglibose is an oral antidiabetic medication classified as an alpha-glucosidase inhibitor, primarily used to manage type 2 diabetes mellitus. Below are its key details:

Mechanism of Action

Inhibits alpha-glucosidase enzymes: Delays the breakdown of carbohydrates (e.g., starch, sucrose) into monosaccharides (e.g., glucose) in the small intestine, reducing postprandial blood glucose spikes.

Indications

Type 2 diabetes: Especially effective for patients with predominant postprandial hyperglycemia. Often combined with other antidiabetic agents (e.g., metformin).

Dosage & Administration

Timing: Taken orally immediately before meals.

Typical dose: 0.2–0.3 mg three times daily (with meals), adjusted under medical supervision.

Advantages

Targeted glucose control: Specifically lowers postprandial glucose levels, minimizing fluctuations.

Low hypoglycemia risk: Monotherapy rarely causes hypoglycemia.

Common Side Effects

Gastrointestinal: Abdominal distension, diarrhea, flatulence (due to undigested carbohydrates fermenting in the colon).

Allergic reactions: Rare (e.g., rash, itching).

Contraindications & Precautions

Contraindications: Severe ketoacidosis, diabetic coma, inflammatory bowel disease (e.g., ulcerative colitis).

Special populations: Use with caution in pregnant or breastfeeding women; dosage adjustment needed in hepatic or renal impairment.

Drug interactions: Avoid concomitant use with digestive enzymes (e.g., pancreatin), which may reduce efficacy.

Comparison with Other Alpha-Glucosidase Inhibitors

Acarbose: Voglibose has a stronger inhibitory effect and potentially milder gastrointestinal side effects.

Miglitol: Voglibose acts locally in the gut with minimal systemic absorption.

Research Developments

Investigated for potential roles in prediabetes or obesity management.

Voglibose aids glycemic control by slowing carbohydrate absorption. It should be combined with dietary and exercise management, with regular monitoring of blood glucose and liver/kidney function. Medical consultation is essential before use.